James Lundy Comments on SEC Casework Backlog as Federal Government Reopens
November 13, 2025
Law360
Foley & Lardner LLP partner James Lundy shared insight on potential delays at the U.S. Securities and Exchange Commission following the end of the federal government shutdown in the Law360 article, “As Backlogged SEC Reopens, Attys Jostle To ‘Get In Line’.”
Lundy said that paused litigation may begin to resume as early as next week, though he cautioned that timing will be “judge-dependent,” with some expecting immediate resumption of cases and others seeking a revised schedule.
“Defense counsel has a view on it, and defense counsel may aggressively want to push litigation, so they may want to get before the judges as soon as possible and get things back on track,” Lundy added.
(Subscription required)
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.